XORTX Therapeutics (XRTX) Accumulated Expenses (2020 - 2021)
XORTX Therapeutics' (XRTX) quarterly Accumulated Expenses came in at $230303.9 in Q4 2021, down 53.39% YoY from $494160.4 in Q4 2020, and down 53.39% on a QoQ basis from $494160.4 in Q4 2020.
XORTX Therapeutics (XRTX) Accumulated Expenses (2020 - 2021) Analysis & Trends
XORTX Therapeutics (XRTX) has 2 years of Accumulated Expenses data on file, last reported at $230303.9 in Q4 2021.
- Quarterly Accumulated Expenses fell 53.39% year-over-year to $230303.9 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $230303.9 (down 53.39% YoY) and the FY2021 annual result came in at $231644.9, down 53.12% from the prior year.
- Accumulated Expenses declined to $230303.9 in Q4 2021, from $494160.4 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $494160.4 in Q4 2020 to a low of $230303.9 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 230,303.88 |
| Dec 31, 2020 | 494,160.39 |